Etirinotecan pegol

Drug Profile

Etirinotecan pegol

Alternative Names: Irinotecan - Nektar Therapeutics; NKTR-102; ONZEALD; PEG-Irinotecan; Pegylated irinotecan - Nektar Therapeutics

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Nektar Therapeutics
  • Developer Clovis Oncology; Mayo Clinic; Nektar Therapeutics; Roswell Park Cancer Institute; Stanford University School of Medicine; University of Pennsylvania Cancer Center
  • Class Alkaloids; Antineoplastics; Camptothecins; Heterocyclic compounds with 4 or more rings; Indolizines; Piperidines; Polyethylene glycols; Quinolines
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Breast cancer
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Breast cancer
  • Phase II Colorectal cancer; Glioma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
  • Phase I Solid tumours
  • No development reported Cervical cancer

Most Recent Events

  • 01 Nov 2016 Nektar Therapeutics initiates the phase III ATTAIN trial for Breast cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, infusion) (NCT02915744)
  • 23 Sep 2016 Nektar Therapeutics plans the phase III ATTAIN trial for Breast cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, infusion) (NCT02915744)
  • 04 Aug 2016 The Committee for Medicinal Products for Human Use (CHMP) of the EMA grants accelerated assessment review status for the approval of Etirinotecan pegol
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top